Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04968834 · ClinicalTrials.gov registry record

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

A clinical trial of Leukemia and Myelodysplastic Syndromes, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
300
Enrollment target
8
Study locations

NCT04968834 is a study of Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 300 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (38% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04968834, a study of Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
300 participants
Enrollment target
8
Study locations

Study Summary

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.

Interventions

  • GENETIC Genomic profiling

Study Locations (8)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Connecticut

  • Connecticut Children's Medical Center - Hartford

Maine

  • Maine Medical Center - Portland

New Hampshire

  • Dartmouth-Hitchcock - Lebanon

New York

  • Albany Medical Center - Albany

Rhode Island

  • Lifespan Cancer Institute - Providence

Vermont

  • University of Vermont Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-06-11
Est. Completion 2033-06

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04968834

The ClinicalTrials.gov registry entry for NCT04968834 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (38% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Genomic profiling is the first listed.

NCT04968834 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, Connecticut, Maine.

Frequently Asked Questions

What is clinical trial NCT04968834 about?

NCT04968834 is a clinical study titled "Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy". This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and ...

What is the current status of trial NCT04968834?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-11. Estimated completion is 2033-06.

What conditions does trial NCT04968834 study?

This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome.

What interventions are being tested in trial NCT04968834?

The interventions under investigation include: Genomic profiling (GENETIC).

Who is sponsoring clinical trial NCT04968834?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04968834 being conducted?

This trial has 8 study locations across Connecticut, Maine, Massachusetts, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.